Epiregulin (EPR)

Epiregulin (EPR) is a member of the EGF family of growth factors that is primarily expressed in the placenta and macrophages. High levels of expression have been detected in various carcinomas. Epiregulin also stimulates the proliferation of fibroblasts, smooth muscle cells, and hepatocytes, and has been shown to inhibit the growth of several epithelial tumor cells. Epiregulin has been implicated in the implantation process during pregnancy.

Swiss-Prot Accession Number: O14944


 
Therapy Indications
Cancer
Cardiac and Vascular Markers/Disease
 
Myriad RBM Publications Publications
Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. (2020) Colombo M, McGurnaghan SJ, Blackbourn LAK, Dalton RN, Dunger D, Bell S, Petrie JR, Green F, MacRury S, McKnight JA, Chalmers J, Collier A, McKeigue PM, Colhoun HM, Scottish Diabetes Research Network (SDRN) Type 1 Bioresource Investigators Diabetologia
Speak to a Scientist